Timing of referral for genetic counseling and genetic testing in patients with ovarian, fallopian tube, or primary peritoneal carcinoma

Akiva P. Novetsky, Kylie Smith, Sheri A. Babb, Donna B. Jeffe, Andrea R. Hagemann, Premal H. Thaker, Matthew A. Powell, David G. Mutch, L. Stewart Massad, Israel Zighelboim

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Objective: The objective of this study was to assess patients' preferences of the timing of referral for genetic counseling and testing in relation to the diagnosis, treatment, and recurrence of ovarian, tubal, or primary peritoneal cancers. Methods: Ninety-two patients who underwent counseling and testing by 1 certified genetic counselorwere identified. An introductory letter, consent form, and questionnairewere mailed to gather information regarding factors influencing the decision to undergo genetic counseling and testing and opinions regarding optimal timing. Medical records were reviewed for demographic and clinical data. Results: Of 47 consenting women, 45 underwent testing. Eight (18%) were found to have a genetic mutation. Women lacked consensus about the optimal time for referral for and to undergo genetic testing, although women with stage I disease preferred testing after completion of chemotherapy. Most women were comfortable receiving the results by phone, but one third preferred an office visit. Conclusions: Patients' views regarding the best time to be referred for and undergo counseling and testing varied greatly. Because of the high mortality of this disease, clinicians should discuss referral early and personalize the timing to each patient. The subset of patients who prefer results disclosure during an office visit should be identified at the time of their initial counseling.

Original languageEnglish (US)
Pages (from-to)1016-1021
Number of pages6
JournalInternational Journal of Gynecological Cancer
Volume23
Issue number6
DOIs
StatePublished - Jul 2013
Externally publishedYes

Fingerprint

Fallopian Tubes
Genetic Counseling
Genetic Testing
Referral and Consultation
Carcinoma
Counseling
Office Visits
Consent Forms
Patient Preference
Disclosure
Medical Records
Consensus
Demography
Recurrence
Drug Therapy
Mutation
Mortality
Neoplasms
Therapeutics

Keywords

  • BRCA mutation
  • Genetic counseling
  • Genetic testing
  • Ovarian/fallopian tube/primary peritoneal cancer
  • Timing

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Timing of referral for genetic counseling and genetic testing in patients with ovarian, fallopian tube, or primary peritoneal carcinoma. / Novetsky, Akiva P.; Smith, Kylie; Babb, Sheri A.; Jeffe, Donna B.; Hagemann, Andrea R.; Thaker, Premal H.; Powell, Matthew A.; Mutch, David G.; Massad, L. Stewart; Zighelboim, Israel.

In: International Journal of Gynecological Cancer, Vol. 23, No. 6, 07.2013, p. 1016-1021.

Research output: Contribution to journalArticle

Novetsky, AP, Smith, K, Babb, SA, Jeffe, DB, Hagemann, AR, Thaker, PH, Powell, MA, Mutch, DG, Massad, LS & Zighelboim, I 2013, 'Timing of referral for genetic counseling and genetic testing in patients with ovarian, fallopian tube, or primary peritoneal carcinoma', International Journal of Gynecological Cancer, vol. 23, no. 6, pp. 1016-1021. https://doi.org/10.1097/IGC.0b013e3182994365
Novetsky, Akiva P. ; Smith, Kylie ; Babb, Sheri A. ; Jeffe, Donna B. ; Hagemann, Andrea R. ; Thaker, Premal H. ; Powell, Matthew A. ; Mutch, David G. ; Massad, L. Stewart ; Zighelboim, Israel. / Timing of referral for genetic counseling and genetic testing in patients with ovarian, fallopian tube, or primary peritoneal carcinoma. In: International Journal of Gynecological Cancer. 2013 ; Vol. 23, No. 6. pp. 1016-1021.
@article{c363b3fe49d540fa9fce4d00d48454dd,
title = "Timing of referral for genetic counseling and genetic testing in patients with ovarian, fallopian tube, or primary peritoneal carcinoma",
abstract = "Objective: The objective of this study was to assess patients' preferences of the timing of referral for genetic counseling and testing in relation to the diagnosis, treatment, and recurrence of ovarian, tubal, or primary peritoneal cancers. Methods: Ninety-two patients who underwent counseling and testing by 1 certified genetic counselorwere identified. An introductory letter, consent form, and questionnairewere mailed to gather information regarding factors influencing the decision to undergo genetic counseling and testing and opinions regarding optimal timing. Medical records were reviewed for demographic and clinical data. Results: Of 47 consenting women, 45 underwent testing. Eight (18{\%}) were found to have a genetic mutation. Women lacked consensus about the optimal time for referral for and to undergo genetic testing, although women with stage I disease preferred testing after completion of chemotherapy. Most women were comfortable receiving the results by phone, but one third preferred an office visit. Conclusions: Patients' views regarding the best time to be referred for and undergo counseling and testing varied greatly. Because of the high mortality of this disease, clinicians should discuss referral early and personalize the timing to each patient. The subset of patients who prefer results disclosure during an office visit should be identified at the time of their initial counseling.",
keywords = "BRCA mutation, Genetic counseling, Genetic testing, Ovarian/fallopian tube/primary peritoneal cancer, Timing",
author = "Novetsky, {Akiva P.} and Kylie Smith and Babb, {Sheri A.} and Jeffe, {Donna B.} and Hagemann, {Andrea R.} and Thaker, {Premal H.} and Powell, {Matthew A.} and Mutch, {David G.} and Massad, {L. Stewart} and Israel Zighelboim",
year = "2013",
month = "7",
doi = "10.1097/IGC.0b013e3182994365",
language = "English (US)",
volume = "23",
pages = "1016--1021",
journal = "International Journal of Gynecological Cancer",
issn = "1048-891X",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Timing of referral for genetic counseling and genetic testing in patients with ovarian, fallopian tube, or primary peritoneal carcinoma

AU - Novetsky, Akiva P.

AU - Smith, Kylie

AU - Babb, Sheri A.

AU - Jeffe, Donna B.

AU - Hagemann, Andrea R.

AU - Thaker, Premal H.

AU - Powell, Matthew A.

AU - Mutch, David G.

AU - Massad, L. Stewart

AU - Zighelboim, Israel

PY - 2013/7

Y1 - 2013/7

N2 - Objective: The objective of this study was to assess patients' preferences of the timing of referral for genetic counseling and testing in relation to the diagnosis, treatment, and recurrence of ovarian, tubal, or primary peritoneal cancers. Methods: Ninety-two patients who underwent counseling and testing by 1 certified genetic counselorwere identified. An introductory letter, consent form, and questionnairewere mailed to gather information regarding factors influencing the decision to undergo genetic counseling and testing and opinions regarding optimal timing. Medical records were reviewed for demographic and clinical data. Results: Of 47 consenting women, 45 underwent testing. Eight (18%) were found to have a genetic mutation. Women lacked consensus about the optimal time for referral for and to undergo genetic testing, although women with stage I disease preferred testing after completion of chemotherapy. Most women were comfortable receiving the results by phone, but one third preferred an office visit. Conclusions: Patients' views regarding the best time to be referred for and undergo counseling and testing varied greatly. Because of the high mortality of this disease, clinicians should discuss referral early and personalize the timing to each patient. The subset of patients who prefer results disclosure during an office visit should be identified at the time of their initial counseling.

AB - Objective: The objective of this study was to assess patients' preferences of the timing of referral for genetic counseling and testing in relation to the diagnosis, treatment, and recurrence of ovarian, tubal, or primary peritoneal cancers. Methods: Ninety-two patients who underwent counseling and testing by 1 certified genetic counselorwere identified. An introductory letter, consent form, and questionnairewere mailed to gather information regarding factors influencing the decision to undergo genetic counseling and testing and opinions regarding optimal timing. Medical records were reviewed for demographic and clinical data. Results: Of 47 consenting women, 45 underwent testing. Eight (18%) were found to have a genetic mutation. Women lacked consensus about the optimal time for referral for and to undergo genetic testing, although women with stage I disease preferred testing after completion of chemotherapy. Most women were comfortable receiving the results by phone, but one third preferred an office visit. Conclusions: Patients' views regarding the best time to be referred for and undergo counseling and testing varied greatly. Because of the high mortality of this disease, clinicians should discuss referral early and personalize the timing to each patient. The subset of patients who prefer results disclosure during an office visit should be identified at the time of their initial counseling.

KW - BRCA mutation

KW - Genetic counseling

KW - Genetic testing

KW - Ovarian/fallopian tube/primary peritoneal cancer

KW - Timing

UR - http://www.scopus.com/inward/record.url?scp=84880275062&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880275062&partnerID=8YFLogxK

U2 - 10.1097/IGC.0b013e3182994365

DO - 10.1097/IGC.0b013e3182994365

M3 - Article

C2 - 23748176

AN - SCOPUS:84880275062

VL - 23

SP - 1016

EP - 1021

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

SN - 1048-891X

IS - 6

ER -